WO2001026470A1 - Suppressor cells for prevention and treatment of immune responses in transplantation - Google Patents

Suppressor cells for prevention and treatment of immune responses in transplantation Download PDF

Info

Publication number
WO2001026470A1
WO2001026470A1 PCT/US2000/028011 US0028011W WO0126470A1 WO 2001026470 A1 WO2001026470 A1 WO 2001026470A1 US 0028011 W US0028011 W US 0028011W WO 0126470 A1 WO0126470 A1 WO 0126470A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
suppressor
transplant
recipient
donor
Prior art date
Application number
PCT/US2000/028011
Other languages
French (fr)
Inventor
Kevin Mcintosh
Elena Klushnenkova
Original Assignee
Osiris Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics, Inc. filed Critical Osiris Therapeutics, Inc.
Priority to DE60026561T priority Critical patent/DE60026561T2/en
Priority to AU10778/01A priority patent/AU775647B2/en
Priority to CA002382737A priority patent/CA2382737A1/en
Priority to JP2001529270A priority patent/JP2003511398A/en
Priority to EP00972063A priority patent/EP1220611B1/en
Publication of WO2001026470A1 publication Critical patent/WO2001026470A1/en
Priority to CY20061100708T priority patent/CY1106437T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Definitions

  • the present invention relates to inhibiting an immune response to an alloantigen and further relates to inhibiting and/or preventing reactivation of previously activated T cells. More particularly, the present invention relates to the field of preventing, reducing or treating an immune response caused by immune effector cells to foreign tissue and/or cells and/or organs. The invention further relates to preventing, reducing or treating transplant rejection and/or graft versus host reaction.
  • Tolerance is the acquired lack of specific responsiveness to an antigen to which an immune response would normally occur.
  • To induce tolerance there must be an exposure to a tolerizing antigen, which results in the death or functional inactivation of certain lymphocytes.
  • Complete tolerance is characterized by the lack of a detectable immune response to the second antigenic challenge. Partial tolerance is typified by the quantitative reduction of an immune response.
  • the immune system does not distinguish beneficial intruders, such as transplanted tissue, from those that are harmful, and thus the immune system rejects transplanted tissue or organs.
  • Rejection of transplanted organs is significantly mediated by alloreactive T cells present in the host which recognize donor alloantigens or xenoantigens.
  • patients are treated with powerful immunosuppressive drugs.
  • the infusion of individuals with drugs that prevent or suppress a T-cell immune response does inhibit transplant rejection, but can also result in general immune suppression, toxicity and even death due to opportunistic infections. Because of the toxicity and incomplete response rate to conventional treatment of donor tissue rejection, alternative approaches are needed to treat patients who cannot withstand or do not respond to current modes of drug therapy.
  • graft-versus-host disease there is a need for the prevention and/or reduction of an unwanted immune response by a host to a transplant by immune effector cells as a method to avert host rejection of donor tissue. Also advantageous would be a method to eliminate or reduce an unwanted immune response by a donor tissue against a recipient tissue, known as graft-versus-host disease.
  • mesenchymal stem cells can induce allo- activated T-cells to become suppressive for allogeneic responses, and that human suppressor cells can be used in transplantation to ameliorate a response by the immune system such that an immune response to an antigen(s) will be reduced or eliminated.
  • a method for reducing or suppressing an immune response caused by T cells responding to an alloantigen, in particular allogeneic tissue, organ or cells wherein the immune response is reduced or suppressed by the use of suppressor T cells.
  • the suppressor T cells may be autologous to the T cells (obtained from the same host), or may be allogeneic to the T-cells.
  • the mesenchymal stem cells that are used may be autologous to the T cells, or may be allogeneic to the T-cells.
  • the mesenchymal stem cells are autologous to the T-cells.
  • suppressor T cells are used to suppress or ameliorate an immune response to a transplant (tissue, organ, cells, etc.) by administering to the transplant recipient suppressor T cells in an amount effective to suppress or ameliorate an immune response against the transplant.
  • the suppressor T cells may be autologous to the transplant recipient, or the suppressor T- cells may be allogeneic to the transplant recipient.
  • the suppressor T-cells are autologous to the transplant recipient.
  • one method of the present invention provides contacting the recipient of donor tissue with autologous suppressor T cells.
  • the method involves administering suppressor T cells to the recipient of donor tissue.
  • the suppressor T cells can be administered to the recipient before or at the same time as the transplant or subsequent to the transplant.
  • the suppressor T cells can also be administered to the recipient as part of the transplant.
  • the present invention provides a method for reducing or ameliorating an immune response by providing to the recipient donor tissue or organ that is perfused with or includes suppressor T cells autologous to the T cells.
  • the suppressor T cells ameliorate an immune response by the recipient's T cells against the foreign tissue when it is transplanted into the recipient.
  • the method of the present invention provides treating a patient who has received a transplant, in order to reduce the severity of or eliminate a rejection episode against the transplant, by administering to the recipient of donor tissue suppressor T cells after the donor tissue has been transplanted into the recipient.
  • the suppressor T cells preferably are autologous to the recipient.
  • the presentation of suppressor T cells to a recipient undergoing an adverse immune response to a transplant induces nonresponsiveness of T cells to further antigenic stimulation thereby reducing or eliminating an adverse response by activated T cells to donor tissue or organ.
  • a method of reducing an immune response by donor tissue, organ or cells against a recipient comprising treating the donor tissue, organ or cells with suppressor T cells ex vivo prior to transplantation of the tissue, organ or cells into the recipient.
  • the suppressor T cells reduce the responsiveness of T cells in the transplant that may be subsequently activated against recipient antigen presenting cells such that the transplant may be introduced into the recipient's (host's) body without the occurrence of, or with a reduction in, an adverse response of the transplant to the host.
  • graft versus host disease may be averted.
  • the donor transplant may be first exposed to recipient or third party tissue or cells ex vivo, to activate the T cells in the donor transplant.
  • the donor transplant is then contacted with suppressor T cells.
  • the suppressor T cells will reduce or inhibit an adverse secondary immune response by T cells in the donor transplant against antigenic stimulation by the recipient when the donor transplant is subsequently placed into the recipient.
  • the suppressor T cells can be obtained from the recipient prior to the transplant.
  • the suppressor T cells can be isolated and stored frozen until needed.
  • the suppressor T cells may also be culture-expanded to desired amounts and stored until needed.
  • the suppressor T cells are administered to the recipient in an amount effective to reduce or eliminate an ongoing adverse immune response caused by the donor transplant against the recipient (host).
  • the presentation of the suppressor T cells to the recipient undergoing an adverse immune response caused by a transplant inhibits the ongoing response and prevents restimulation of the T cells thereby reducing or eliminating an adverse response by activated T cells to recipient tissue.
  • human suppressor T cells are employed to treat transplant rejection and or graft versus host disease as a result of a transplant and or to prevent or reduce transplant rejection and or graft versus host disease.
  • Human suppressor T cells may also be employed to facilitate the use of xenogeneic grafts or transplants.
  • Fig. 1 shows the level of restimulation of suppressor T cells in a mixed lymphocyte reaction using original donor stimulator cells (same donor stimulators used to generate the suppressor T cells) at day 0.
  • Suppressor T cells (T2) did not respond to restimulation with original donor PBMCs or phytohemagglutin (PHA).
  • CD8 cell depleted T cell population (T3) resulted in partial restoration of responsiveness.
  • T cells cultured without MSCs (Tl) responded well in the secondary mixed lymphocyte reaction and to PHA.
  • Fig. 2 shows the level of suppression of an ongoing mixed lymphocyte reaction by suppressor T cells at day 0 (Fig. 2A), day 1 (Fig. 2B) and day 2 (Fig. 2C) after addition of the suppressor T cells to the reaction cultures.
  • the stimulator cells in the mixed lymphocyte reaction are from the same donor as the stimulator cells used to generate the suppressor T cells.
  • Suppressor T cells (T2) suppressed an on-going mixed lymphocyte reaction early and at very low cell number per well.
  • CD8 cell depleted cell population (T3) resulted in delayed and only partial suppression.
  • T cells cultured without MSCs (Tl) did not suppress, and even enhanced the mixed lymphocyte reaction.
  • Fig. 3 shows the level of suppression of an ongoing mixed lymphocyte reaction by suppressor T cells at day 0 (Fig. 3A), day 1 (Fig. 3B) and day 2 (Fig. 3C) after addition of the suppressor T cells to the reaction cultures.
  • the stimulator cells in the mixed lymphocyte reaction are from a third party donor (different donor than the original stimulator cell donor and suppressor T cell donor).
  • Suppressor T cells (T2) suppressed an on-going mixed lymphocyte reaction early and at very low cell number per well.
  • CD8 cell depleted cell population (T3) resulted in delayed and only partial suppression.
  • T cells cultured without MSCs (Tl) did not suppress, and even enhanced the mixed lymphocyte reaction.
  • Fig. 4 shows the level of suppression of PHA proliferative response by suppressor T cells at day 1 (Fig. 4A), day 2 (Fig. 4B) and day 3 (Fig. 4C).
  • Suppressor T cells suppressed PHA-induced proliferation of autologous PBMCs whereas T cells cultured alone accelerated the PHA response. Depletion of CD8 cells resulted in delayed and only partial suppression.
  • suppressor T cells are T cells which have been primed, for example, in a mixed lymphocyte reaction by exposure to an alloantigen, and subsequently cultured with mesenchymal stem cells (autologous or allogeneic to the T cells - same as stimulator or third party). These suppressor T cells are not restimulated when placed again in a mixed lymphocyte reaction and exposed to an alloantigen either the same or third party alloantigen as the original stimulator cells.
  • Donor antigen refers to antigens expressed by the donor tissue to be transplanted into the recipient. Alloantigens are antigens which differ from antigens expressed by the recipient. Donor tissue, organs or cells to be transplanted is the transplant. Examples of transplants include, but are not limited to, skin, bone marrow, and solid organs such as heart, pancreas, kidney, lung and liver. The pancreas and liver may be reduced to single cell suspensions for transplant.
  • suppressor T cells can suppress an MLR between allogeneic cells.
  • Suppressor T cells actively reduced the allogeneic T cell response in mixed lymphocyte reactions in a dose dependent manner.
  • the present invention provides a method of reducing, inhibiting or eliminating an immune response by administering suppressor T cells to a recipient of a donor tissue, organ or cells.
  • the suppressor T cells are administered to the recipient contemporaneously with the transplant.
  • the suppressor T cells can be administered prior to the administration of the transplant.
  • the suppressor T cells can be administered to the recipient about 3 to 7 days before transplantation of the donor tissue.
  • suppressor T cells can be used to condition a recipient's immune system to donor or foreign tissue by administering to the recipient, prior to, or at the same time as transplantation of the donor tissue, suppressor T cells in an amount effective to reduce or eliminate an immune response against the transplant by the recipient's T cells.
  • the suppressor T cells affect the T cells of the recipient such that the T cell response is reduced or eliminated when presented with donor or foreign tissue.
  • host rejection of the transplant may be avoided or the severity thereof reduced.
  • the present invention provides a method for treating a patient who is undergoing an adverse immune response to a transplant by administering suppressor T cells to such patient in an amount effective to reduce or suppress the immune response.
  • the suppressor T cells may be obtained from the transplant recipient, from the transplant donor, or from a third party.
  • the present invention provides a method to reduce or inhibit or eliminate an immune response by a donor transplant against a recipient thereof (graft versus host). Accordingly, the invention provides contacting a donor organ or tissue with suppressor T cells prior to transplant. The suppressor T cells ameliorate, inhibit or reduce an adverse response by the donor transplant against the recipient.
  • the donor transplant prior to transplant the donor transplant is treated with allogeneic (recipient) tissue or cells which activate the T cells in the donor transplant.
  • the donor transplant is then treated with autologous suppressor T cells prior to transplant.
  • the suppressor T cells prevent restimulation, or induce hyporesponsiveness, of the T cells to subsequent antigenic stimulation.
  • Donor marrow can be pretreated with donor suppressor T cells prior to implant of the bone marrow or peripheral blood stem cells into the recipient.
  • the donor marrow is first exposed to recipient tissue/cells and then treated with suppressor T cells.
  • suppressor T cells Although not being limited thereto, it is believed that the initial contact with recipient tissue or cells functions to activate the T cells in the marrow. Subsequent treatment with the suppressor T cells inhibits or eliminates further activation of the T cells in the marrow, thereby reducing or eliminating an adverse affect by the donor tissue, i.e. the therapy reduces or eliminates graft versus host response.
  • a transplant recipient suffering from graft versus host disease may be treated to reduce or eliminate the severity thereof by administering to such recipient suppressor T cells in an amount effective to reduce or eliminate a graft rejection of the host.
  • the suppressor T cells inhibit or suppress the activated T cells in the donor tissue from mounting an immune response against the recipient, thereby reducing or eliminating a graft versus host response.
  • the recipient's suppressor T cells may be obtained from the transplant donor or the recipient or a third party prior to the transplantation and may be stored and/or culture-expanded to provide a reserve of suppressor T cells in sufficient amounts for treating an ongoing graft attack against host.
  • the donor tissue is exposed to suppressor T cells such that the suppressor T cells integrate into the organ graft itself prior to transplantation.
  • an immune response against the graft caused by any alloreactive recipient cells that escaped standard treatment to prevent transplant rejection, e.g., drug-mediated immunosuppression, would be suppressed by the suppressor T cells present in the graft.
  • the suppressor T cells are preferably autologous to the recipient.
  • the suppressor T cells of the present invention can be used in conjunction with current modes of treating donor tissue rejection or graft versus host disease.
  • An advantage of such use is that by ameliorating the severity of the immune response in a transplant recipient, the amount of drug used in treatment and/or the frequency of administration of drug therapy can be reduced, resulting in alleviation of general immune suppression and unwanted side effects.
  • the invention described herein provides for preventing or treating transplant rejection by administering the suppressor T cells in a prophylactic or therapeutically effective amount for the prevention or treatment or amelioration of transplant rejection of an organ, tissue or cells from the same species, or a xenograft organ or tissue transplant and or graft versus host disease.
  • Administration of a single dose of suppressor T cells may be effective to reduce or eliminate the T cell response to tissue allogeneic to the T cells or to "non-self tissue, particularly in the case where the T lymphocytes retain their nonresponsive character
  • the dosage of the suppressor T cells varies within wide limits and will, of course be fitted to the individual requirements in each particular case. In general, in the case of parenteral administration, it is customary to administer from about 0.01 to about 5 million cells per kilogram of recipient body weight. The number of cells used will depend on the weight and condition of the recipient, the number of or frequency of administrations, and other variables known to those of skill in the art.
  • the suppressor T cells can be administered by a route which is suitable for the tissue, organ or cells to be transplanted. They can be administered systemically, i.e., parenterally, by intravenous injection or can be targeted to a particular tissue or organ, such as bone marrow.
  • the suppressor T cells can be administered via a subcutaneous implantation of cells or by injection of stem cell into connective tissue, for example muscle.
  • the cells can be suspended in an appropriate diluent, at a concentration of from about 0.01 to about 5 x 10 6 cells/ ml.
  • Suitable excipients for injection solutions are those that are biologically and physiologically compatible with the cells and with the recipient, such as buffered saline solution or other suitable excipients.
  • the composition for administration must be formulated, produced and stored according to standard methods complying with proper sterility and stability.
  • mesenchymal stem cells can be isolated, preferably from bone marrow, purified, and expanded in culture, i.e. in vitro, to obtain sufficient numbers of cells for use in the methods described herein.
  • Mesenchymal stem cells the formative pluripotent blast cells found in the bone, are normally present at very low frequencies in bone marrow (1 :100,000) and other mesenchymal tissues. See, Caplan and Haynesworth, U.S. Patent No. 5,486,359.
  • Gene transduction of mesenchymal stem cells is disclosed in Gerson et al U.S. Patent No. 5,591,625.
  • the mixed lymphocyte reaction measures the compatibility of the donor's surface antigens and is an indication of the likelihood of rejection of donor tissue.
  • Cell surface antigens responsible for eliciting transplant rejection are class I and class II
  • PBMC peripheral blood mononuclear cells
  • the cells were washed twice with MSC medium (DMEM with low glucose and 10% FCS) and re-suspended in assay medium (ISCOVE'S with 25 mM Hepes, 1 mM sodium pyruvate, 100 ⁇ M non- essential amino acids, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 0.25 ⁇ g/ml amphotericin B, 5.5x10 ⁇ 5 M 2-mercaptoethanol (all reagents from GibcoBLR) and 5% human AB serum (Sigma, MLR tested)).
  • MSC medium DMEM with low glucose and 10% FCS
  • ISCOVE'S with 25 mM Hepes, 1 mM sodium pyruvate, 100 ⁇ M non- essential amino acids, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 0.25 ⁇ g/ml amphotericin B, 5.5x10 ⁇ 5 M 2-mercaptoethanol (all reagents from Gib
  • PBMCs from donor 155 were depleted of monocytes and B cells by immunomagnetic negative selection.
  • PBMCs were incubated with mouse anti -human CD 19 and CD 14 mAbs (no azide/low endotoxin (NA/LE) format) followed by biotin-conjugated goat anti-mouse IgG (multiple adsorption) Ab (all reagents from Pharmingen) and streptavidin microbeads (Miltenyi Biotec). Cells were then separated using a magnetic cell sorter (MACS, Miltenyi Biotec).
  • MNS magnetic cell sorter
  • PBMC from donor 413 were X-ray irradiated with 3600 rad (12 min at 70 kV) using Cabinet X ray system (Faxitron X ray, Buffalo Grove, IL).
  • T cells (15 x 10 6 /dish) from donor 155 were cultured in 10cm tissue culture dishes with PBMC (15 x 10 6 cells/dish) from donor 413 for 7 days. The cells were incubated at 37°C in 5% CO 2 atmosphere for 7 days.
  • MSCs Human MSCs were isolated from donor 273 from bone marrow as described in U.S. Patent No. 5,486,359 and were maintained in culture with MSC medium and were used at passages from 3 to 6. Cells were lifted using 0.05% Trypsin/EDTA solution, washed once with MSC medium. The MSCs (d 273) were plated at 1.0 x 10 6 cells/dish in 10 cm tissue culture dishes, cultured for 4 days, and washed 4 times with PBS-D prior to adding activated T cells (dl55).
  • T cells (dl55) activated in the MLR for 7 days, were collected washed once with MSC medium and re- suspended in assay medium and transferred to the dishes with the pre-plated MSCs (0.5 x 10 6 cells/ml, 1.0 x 10 7 cells/dish) for 3 days at 37°C in 5% CO 2 atmosphere.
  • activated T cells were cultured without MSCs at the same density (the "Tl " population).
  • Cells cultured with MSCs are the "T2" population; the "T3" population was depleted of CD8+ cells as described hereinbelow.
  • T2 population T2 population
  • Aliquots of cells collected before and after depletion were stained with anti-CD4-PE and anti-CD8-APC antibodies (Caltag) and analyzed by FACS.
  • Cells were plated at 5 x 10 4 cells/well each in 96-well tissue culture plates. Alternatively, 5 x 10 4 T cells were stimulated with PHA (5 ⁇ g/ml).
  • An MLR was set up in 96-well tissue culture plates 4 days prior to adding suppressor T cells.
  • 1.5 x 10 5 responder T cells were mixed with the same number of irradiated stimulator cells.
  • T cells from donor 155 autologous to suppressor T cells
  • Stimulator PBMCs were from donor 413 (same as the stimulator for suppressor T cell generation) or from donor 273 (third party to supressors).
  • T cells from donor 155 pre-activated by irradiated PBMCs from donor 413 for 7 days, and cultured alone or with MSCs from donor 273 for 3 days (non- fractionated or CD8 depleted) were used as suppressors. After 4 days of culture, suppressor T cells were added at different numbers per well (from 5 x 10 4 cells/well to 1.56 x 10' cells/well). Cultures were pulsed with [H 3 ]TdR (5 Ci/mmol, 1 ⁇ Ci/well) for 18 hours immediately after plating, or incubated for 1 or 2 days and then pulsed with [H 3 ]TdR for an additional 18 hours.
  • [H 3 ]TdR 5 Ci/mmol, 1 ⁇ Ci/well
  • PBMC from donor 155 autologous to suppressor cells
  • PHA-M 5 ⁇ g/ml
  • T cells from donor 155 were pre-activated by irradiated PBMC from donor 413 for 7 days as described above. These cells were cultured alone or with MSCs from donor 273 for 3 days (non-fractionated or CD8 depleted).
  • Suppressor T cells were added at different number/well (from 5 x 10 4 cells/well to 1.56 x 10 3 cells/well). Cultures were incubated for 1, 2 or 3 days, then pulsed with [H 3 ]TdR (5 Ci/mmol, 1 ⁇ Ci/well) for an additional 18 hours.

Abstract

A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of suppressor T cells effective to reduce or inhibit host rejection of the transplant. The suppressor T cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with suppressor T cells.

Description

SUPPRESSOR CELLS FOR PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATION
The present invention relates to inhibiting an immune response to an alloantigen and further relates to inhibiting and/or preventing reactivation of previously activated T cells. More particularly, the present invention relates to the field of preventing, reducing or treating an immune response caused by immune effector cells to foreign tissue and/or cells and/or organs. The invention further relates to preventing, reducing or treating transplant rejection and/or graft versus host reaction.
Background of the Invention Tolerance is the acquired lack of specific responsiveness to an antigen to which an immune response would normally occur. Typically, to induce tolerance, there must be an exposure to a tolerizing antigen, which results in the death or functional inactivation of certain lymphocytes. Complete tolerance is characterized by the lack of a detectable immune response to the second antigenic challenge. Partial tolerance is typified by the quantitative reduction of an immune response.
Unfortunately, the immune system does not distinguish beneficial intruders, such as transplanted tissue, from those that are harmful, and thus the immune system rejects transplanted tissue or organs. Rejection of transplanted organs is significantly mediated by alloreactive T cells present in the host which recognize donor alloantigens or xenoantigens. At present, in order to prevent or reduce an immune response against a transplant, patients are treated with powerful immunosuppressive drugs. The infusion of individuals with drugs that prevent or suppress a T-cell immune response does inhibit transplant rejection, but can also result in general immune suppression, toxicity and even death due to opportunistic infections. Because of the toxicity and incomplete response rate to conventional treatment of donor tissue rejection, alternative approaches are needed to treat patients who cannot withstand or do not respond to current modes of drug therapy.
Accordingly, there is a need for the prevention and/or reduction of an unwanted immune response by a host to a transplant by immune effector cells as a method to avert host rejection of donor tissue. Also advantageous would be a method to eliminate or reduce an unwanted immune response by a donor tissue against a recipient tissue, known as graft-versus-host disease.
Summary of the Invention It has been discovered that mesenchymal stem cells (MSCs) can induce allo- activated T-cells to become suppressive for allogeneic responses, and that human suppressor cells can be used in transplantation to ameliorate a response by the immune system such that an immune response to an antigen(s) will be reduced or eliminated.
In accordance with one aspect of the invention, there is provided a method for reducing or suppressing an immune response caused by T cells responding to an alloantigen, in particular allogeneic tissue, organ or cells, wherein the immune response is reduced or suppressed by the use of suppressor T cells. The suppressor T cells may be autologous to the T cells (obtained from the same host), or may be allogeneic to the T-cells. In accordance with another aspect of the present invention there is provided a process for preventing restimulation of activated T cells (activated against an alloantigen, in particular an allogeneic organ, tissue or cells) by contacting activated T cells with suppressor T cells in an amount effective to prevent and/or reduce a subsequent T cell response to a foreign antigen. The mesenchymal stem cells that are used may be autologous to the T cells, or may be allogeneic to the T-cells. Preferably, the mesenchymal stem cells are autologous to the T-cells.
In accordance with another aspect of the present invention, suppressor T cells are used to suppress or ameliorate an immune response to a transplant (tissue, organ, cells, etc.) by administering to the transplant recipient suppressor T cells in an amount effective to suppress or ameliorate an immune response against the transplant. The suppressor T cells may be autologous to the transplant recipient, or the suppressor T- cells may be allogeneic to the transplant recipient. Preferably, the suppressor T-cells are autologous to the transplant recipient.
Accordingly, one method of the present invention provides contacting the recipient of donor tissue with autologous suppressor T cells. In one embodiment of this aspect, the method involves administering suppressor T cells to the recipient of donor tissue. The suppressor T cells can be administered to the recipient before or at the same time as the transplant or subsequent to the transplant.
The suppressor T cells can also be administered to the recipient as part of the transplant. To this objective, the present invention provides a method for reducing or ameliorating an immune response by providing to the recipient donor tissue or organ that is perfused with or includes suppressor T cells autologous to the T cells. The suppressor T cells ameliorate an immune response by the recipient's T cells against the foreign tissue when it is transplanted into the recipient. In another embodiment, the method of the present invention provides treating a patient who has received a transplant, in order to reduce the severity of or eliminate a rejection episode against the transplant, by administering to the recipient of donor tissue suppressor T cells after the donor tissue has been transplanted into the recipient. The suppressor T cells preferably are autologous to the recipient. The presentation of suppressor T cells to a recipient undergoing an adverse immune response to a transplant induces nonresponsiveness of T cells to further antigenic stimulation thereby reducing or eliminating an adverse response by activated T cells to donor tissue or organ.
In a further aspect of the present invention, there is provided a method of reducing an immune response by donor tissue, organ or cells against a recipient, i.e. graft versus host response, comprising treating the donor tissue, organ or cells with suppressor T cells ex vivo prior to transplantation of the tissue, organ or cells into the recipient. The suppressor T cells reduce the responsiveness of T cells in the transplant that may be subsequently activated against recipient antigen presenting cells such that the transplant may be introduced into the recipient's (host's) body without the occurrence of, or with a reduction in, an adverse response of the transplant to the host. Thus, what is known as "graft versus host" disease may be averted.
In a preferred embodiment, the donor transplant may be first exposed to recipient or third party tissue or cells ex vivo, to activate the T cells in the donor transplant. The donor transplant is then contacted with suppressor T cells. The suppressor T cells will reduce or inhibit an adverse secondary immune response by T cells in the donor transplant against antigenic stimulation by the recipient when the donor transplant is subsequently placed into the recipient.
The suppressor T cells can be obtained from the recipient prior to the transplant. The suppressor T cells can be isolated and stored frozen until needed. The suppressor T cells may also be culture-expanded to desired amounts and stored until needed. The suppressor T cells are administered to the recipient in an amount effective to reduce or eliminate an ongoing adverse immune response caused by the donor transplant against the recipient (host). The presentation of the suppressor T cells to the recipient undergoing an adverse immune response caused by a transplant inhibits the ongoing response and prevents restimulation of the T cells thereby reducing or eliminating an adverse response by activated T cells to recipient tissue.
Thus, in accordance with preferred embodiments of the present invention, human suppressor T cells are employed to treat transplant rejection and or graft versus host disease as a result of a transplant and or to prevent or reduce transplant rejection and or graft versus host disease. Human suppressor T cells may also be employed to facilitate the use of xenogeneic grafts or transplants.
Brief Description of the Drawings
Fig. 1 shows the level of restimulation of suppressor T cells in a mixed lymphocyte reaction using original donor stimulator cells (same donor stimulators used to generate the suppressor T cells) at day 0. Suppressor T cells (T2) did not respond to restimulation with original donor PBMCs or phytohemagglutin (PHA). CD8 cell depleted T cell population (T3) resulted in partial restoration of responsiveness. T cells cultured without MSCs (Tl) responded well in the secondary mixed lymphocyte reaction and to PHA.
Fig. 2 shows the level of suppression of an ongoing mixed lymphocyte reaction by suppressor T cells at day 0 (Fig. 2A), day 1 (Fig. 2B) and day 2 (Fig. 2C) after addition of the suppressor T cells to the reaction cultures. The stimulator cells in the mixed lymphocyte reaction are from the same donor as the stimulator cells used to generate the suppressor T cells. Suppressor T cells (T2) suppressed an on-going mixed lymphocyte reaction early and at very low cell number per well. CD8 cell depleted cell population (T3) resulted in delayed and only partial suppression. T cells cultured without MSCs (Tl) did not suppress, and even enhanced the mixed lymphocyte reaction.
Fig. 3 shows the level of suppression of an ongoing mixed lymphocyte reaction by suppressor T cells at day 0 (Fig. 3A), day 1 (Fig. 3B) and day 2 (Fig. 3C) after addition of the suppressor T cells to the reaction cultures. The stimulator cells in the mixed lymphocyte reaction are from a third party donor (different donor than the original stimulator cell donor and suppressor T cell donor). Suppressor T cells (T2) suppressed an on-going mixed lymphocyte reaction early and at very low cell number per well. CD8 cell depleted cell population (T3) resulted in delayed and only partial suppression. T cells cultured without MSCs (Tl) did not suppress, and even enhanced the mixed lymphocyte reaction.
Fig. 4 shows the level of suppression of PHA proliferative response by suppressor T cells at day 1 (Fig. 4A), day 2 (Fig. 4B) and day 3 (Fig. 4C). Suppressor T cells suppressed PHA-induced proliferation of autologous PBMCs whereas T cells cultured alone accelerated the PHA response. Depletion of CD8 cells resulted in delayed and only partial suppression.
Detailed Description of the Invention As defined herein suppressor T cells are T cells which have been primed, for example, in a mixed lymphocyte reaction by exposure to an alloantigen, and subsequently cultured with mesenchymal stem cells (autologous or allogeneic to the T cells - same as stimulator or third party). These suppressor T cells are not restimulated when placed again in a mixed lymphocyte reaction and exposed to an alloantigen either the same or third party alloantigen as the original stimulator cells.
Donor antigen refers to antigens expressed by the donor tissue to be transplanted into the recipient. Alloantigens are antigens which differ from antigens expressed by the recipient. Donor tissue, organs or cells to be transplanted is the transplant. Examples of transplants include, but are not limited to, skin, bone marrow, and solid organs such as heart, pancreas, kidney, lung and liver. The pancreas and liver may be reduced to single cell suspensions for transplant.
The inventors have discovered that suppressor T cells can suppress an MLR between allogeneic cells. Suppressor T cells actively reduced the allogeneic T cell response in mixed lymphocyte reactions in a dose dependent manner.
Accordingly, the present invention provides a method of reducing, inhibiting or eliminating an immune response by administering suppressor T cells to a recipient of a donor tissue, organ or cells. In one embodiment, the suppressor T cells are administered to the recipient contemporaneously with the transplant. Alternatively, the suppressor T cells can be administered prior to the administration of the transplant. For example, the suppressor T cells can be administered to the recipient about 3 to 7 days before transplantation of the donor tissue.
Thus, suppressor T cells can be used to condition a recipient's immune system to donor or foreign tissue by administering to the recipient, prior to, or at the same time as transplantation of the donor tissue, suppressor T cells in an amount effective to reduce or eliminate an immune response against the transplant by the recipient's T cells.
The suppressor T cells affect the T cells of the recipient such that the T cell response is reduced or eliminated when presented with donor or foreign tissue. Thus, host rejection of the transplant may be avoided or the severity thereof reduced.
Accordingly, the present invention provides a method for treating a patient who is undergoing an adverse immune response to a transplant by administering suppressor T cells to such patient in an amount effective to reduce or suppress the immune response. The suppressor T cells may be obtained from the transplant recipient, from the transplant donor, or from a third party.
In another aspect, the present invention provides a method to reduce or inhibit or eliminate an immune response by a donor transplant against a recipient thereof (graft versus host). Accordingly, the invention provides contacting a donor organ or tissue with suppressor T cells prior to transplant. The suppressor T cells ameliorate, inhibit or reduce an adverse response by the donor transplant against the recipient.
In a preferred embodiment, prior to transplant the donor transplant is treated with allogeneic (recipient) tissue or cells which activate the T cells in the donor transplant. The donor transplant is then treated with autologous suppressor T cells prior to transplant. The suppressor T cells prevent restimulation, or induce hyporesponsiveness, of the T cells to subsequent antigenic stimulation.
Thus, in the context of bone marrow (hematopoietic stem cell) transplantation, attack of the host by the graft can be reduced or eliminated. Donor marrow can be pretreated with donor suppressor T cells prior to implant of the bone marrow or peripheral blood stem cells into the recipient. In a preferred embodiment, the donor marrow is first exposed to recipient tissue/cells and then treated with suppressor T cells. Although not being limited thereto, it is believed that the initial contact with recipient tissue or cells functions to activate the T cells in the marrow. Subsequent treatment with the suppressor T cells inhibits or eliminates further activation of the T cells in the marrow, thereby reducing or eliminating an adverse affect by the donor tissue, i.e. the therapy reduces or eliminates graft versus host response.
In a further embodiment, a transplant recipient suffering from graft versus host disease may be treated to reduce or eliminate the severity thereof by administering to such recipient suppressor T cells in an amount effective to reduce or eliminate a graft rejection of the host. The suppressor T cells inhibit or suppress the activated T cells in the donor tissue from mounting an immune response against the recipient, thereby reducing or eliminating a graft versus host response.
The recipient's suppressor T cells may be obtained from the transplant donor or the recipient or a third party prior to the transplantation and may be stored and/or culture-expanded to provide a reserve of suppressor T cells in sufficient amounts for treating an ongoing graft attack against host.
In yet another method of the present invention, the donor tissue is exposed to suppressor T cells such that the suppressor T cells integrate into the organ graft itself prior to transplantation. In this situation, an immune response against the graft caused by any alloreactive recipient cells that escaped standard treatment to prevent transplant rejection, e.g., drug-mediated immunosuppression, would be suppressed by the suppressor T cells present in the graft. The suppressor T cells are preferably autologous to the recipient.
In accordance with the methods of the present invention described herein, it is contemplated that the suppressor T cells of the present invention can be used in conjunction with current modes of treating donor tissue rejection or graft versus host disease. An advantage of such use is that by ameliorating the severity of the immune response in a transplant recipient, the amount of drug used in treatment and/or the frequency of administration of drug therapy can be reduced, resulting in alleviation of general immune suppression and unwanted side effects.
It is further contemplated that only a single treatment with the suppressor T cells of the present invention may be required, eliminating the need for chronic immunosuppressive drug therapy. Alternatively, multiple administrations of suppressor T cells may be employed. Accordingly, the invention described herein provides for preventing or treating transplant rejection by administering the suppressor T cells in a prophylactic or therapeutically effective amount for the prevention or treatment or amelioration of transplant rejection of an organ, tissue or cells from the same species, or a xenograft organ or tissue transplant and or graft versus host disease.
Administration of a single dose of suppressor T cells may be effective to reduce or eliminate the T cell response to tissue allogeneic to the T cells or to "non-self tissue, particularly in the case where the T lymphocytes retain their nonresponsive character
(i.e., tolerance or anergy) to allogeneic cells after being separated from the suppressor T cells.
The dosage of the suppressor T cells varies within wide limits and will, of course be fitted to the individual requirements in each particular case. In general, in the case of parenteral administration, it is customary to administer from about 0.01 to about 5 million cells per kilogram of recipient body weight. The number of cells used will depend on the weight and condition of the recipient, the number of or frequency of administrations, and other variables known to those of skill in the art. The suppressor T cells can be administered by a route which is suitable for the tissue, organ or cells to be transplanted. They can be administered systemically, i.e., parenterally, by intravenous injection or can be targeted to a particular tissue or organ, such as bone marrow. The suppressor T cells can be administered via a subcutaneous implantation of cells or by injection of stem cell into connective tissue, for example muscle.
The cells can be suspended in an appropriate diluent, at a concentration of from about 0.01 to about 5 x 106 cells/ ml. Suitable excipients for injection solutions are those that are biologically and physiologically compatible with the cells and with the recipient, such as buffered saline solution or other suitable excipients. The composition for administration must be formulated, produced and stored according to standard methods complying with proper sterility and stability.
Although the invention is not limited thereof, mesenchymal stem cells can be isolated, preferably from bone marrow, purified, and expanded in culture, i.e. in vitro, to obtain sufficient numbers of cells for use in the methods described herein. Mesenchymal stem cells, the formative pluripotent blast cells found in the bone, are normally present at very low frequencies in bone marrow (1 :100,000) and other mesenchymal tissues. See, Caplan and Haynesworth, U.S. Patent No. 5,486,359. Gene transduction of mesenchymal stem cells is disclosed in Gerson et al U.S. Patent No. 5,591,625.
It should be understood that the methods described herein may be carried out in a number of ways and with various modifications and permutations thereof that are well known in the art. It may also be appreciated that any theories set forth as to modes of action or interactions between cell types should not be construed as limiting this invention in any manner, but are presented such that the methods of the invention can be more fully understood.
The following examples further illustrate aspects of the present invention.
However, they are in no way a limitation of the teachings or disclosure of the present invention as set forth herein.
The mixed lymphocyte reaction measures the compatibility of the donor's surface antigens and is an indication of the likelihood of rejection of donor tissue. Cell surface antigens responsible for eliciting transplant rejection are class I and class II
MHC antigens. T cells are alloreactive to foreign MHC antigens. Class I and II MHC molecules stimulate the mixed lymphocyte reaction. EXAMPLES Peripheral blood mononuclear cells (PBMC) were prepared by density gradient centrifugation on Ficoll-Paque (Pharmacia). Aliquots of cells were frozen in 90% FCS with 10% DMSO and stored in liquid nitrogen. After thawing, the cells were washed twice with MSC medium (DMEM with low glucose and 10% FCS) and re-suspended in assay medium (ISCOVE'S with 25 mM Hepes, 1 mM sodium pyruvate, 100 μM non- essential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin B, 5.5x10~5M 2-mercaptoethanol (all reagents from GibcoBLR) and 5% human AB serum (Sigma, MLR tested)).
To prepare the T cell-enriched fraction, PBMCs from donor 155 were depleted of monocytes and B cells by immunomagnetic negative selection. PBMCs were incubated with mouse anti -human CD 19 and CD 14 mAbs (no azide/low endotoxin (NA/LE) format) followed by biotin-conjugated goat anti-mouse IgG (multiple adsorption) Ab (all reagents from Pharmingen) and streptavidin microbeads (Miltenyi Biotec). Cells were then separated using a magnetic cell sorter (MACS, Miltenyi Biotec).
PBMC from donor 413 were X-ray irradiated with 3600 rad (12 min at 70 kV) using Cabinet X ray system (Faxitron X ray, Buffalo Grove, IL).
Activation of T cells: T cells (15 x 106/dish) from donor 155 were cultured in 10cm tissue culture dishes with PBMC (15 x 106 cells/dish) from donor 413 for 7 days. The cells were incubated at 37°C in 5% CO2 atmosphere for 7 days.
Co-culture with MSCs: Human MSCs were isolated from donor 273 from bone marrow as described in U.S. Patent No. 5,486,359 and were maintained in culture with MSC medium and were used at passages from 3 to 6. Cells were lifted using 0.05% Trypsin/EDTA solution, washed once with MSC medium. The MSCs (d 273) were plated at 1.0 x 106 cells/dish in 10 cm tissue culture dishes, cultured for 4 days, and washed 4 times with PBS-D prior to adding activated T cells (dl55). T cells (dl55) activated in the MLR for 7 days, were collected washed once with MSC medium and re- suspended in assay medium and transferred to the dishes with the pre-plated MSCs (0.5 x 106 cells/ml, 1.0 x 107 cells/dish) for 3 days at 37°C in 5% CO2 atmosphere. In control cultures activated T cells were cultured without MSCs at the same density (the "Tl " population). Cells cultured with MSCs are the "T2" population; the "T3" population was depleted of CD8+ cells as described hereinbelow.
Immunomagnetic depletion and FACS staining: at the end of culture with MSCs (10 days after initiation of primary culture), T cells were recovered and washed. These are the "suppressor T cells" ("T2 population"). CD8 cells were depleted by negative immunomagnetic selection with anti-CD8 MicroBeads (Miltenyi Biotec) (CD8 depleted ="T3" population). Aliquots of cells collected before and after depletion were stained with anti-CD4-PE and anti-CD8-APC antibodies (Caltag) and analyzed by FACS.
Re-stimulation: T cells activated in MLR for 7 days and cultured without MSCs (Tl) for 3 days, or cultured with MSCs (non-fractionated ("T2") or CD8 depleted ("T3")) were recovered and re-stimulated with irradiated PBMCs autologous to original stimulator (donor 413) or autologous to responder (donor 155). Cells were plated at 5 x 104 cells/well each in 96-well tissue culture plates. Alternatively, 5 x 104 T cells were stimulated with PHA (5 μg/ml).
Cultures were pulsed with [H ]TdR (Amersham) (5 Ci/mmol, 1 μCi/well) for 18 hours immediately after plating, or incubated for 1 , 2 , 3 or 4 days and then pulsed with [H3]TdR) for an additional 18 hours. Cultures were collected using Harvester 96 (Tomtec), filters were analyzed using Microbeta Trilux liquid scintillation and luminescence counter (E.G.&G Wallac). The results are shown in Figure 1. Suppressor T cells (T2) did not respond to restimulation with original donor PBMCs or PHA. Culture with cells depleted of CD8+ cells from the suppressor T cell population (T3) resulted in partial restoration of responsiveness. T cells cultured without MSCs (Tl) responded well in the secondary mixed lymphocyte reaction and to PHA.
Suppression of ongoing MLR by suppressor T cells
An MLR was set up in 96-well tissue culture plates 4 days prior to adding suppressor T cells. In MLR, 1.5 x 105 responder T cells were mixed with the same number of irradiated stimulator cells. T cells from donor 155 (autologous to suppressor T cells) were prepared from PBMC by negative immunomagnetic selection with anti- CD 14 and anti-CD 19 MicroBeads. Stimulator PBMCs were from donor 413 (same as the stimulator for suppressor T cell generation) or from donor 273 (third party to supressors). T cells from donor 155 pre-activated by irradiated PBMCs from donor 413 for 7 days, and cultured alone or with MSCs from donor 273 for 3 days (non- fractionated or CD8 depleted) were used as suppressors. After 4 days of culture, suppressor T cells were added at different numbers per well (from 5 x 104 cells/well to 1.56 x 10' cells/well). Cultures were pulsed with [H3]TdR (5 Ci/mmol, 1 μCi/well) for 18 hours immediately after plating, or incubated for 1 or 2 days and then pulsed with [H3]TdR for an additional 18 hours.
The results are shown in Figures 2 and 3. Suppressor T cells ("preculrured with MSC") suppressed an on-going mixed lymphocyte reaction early and at a very low cell number per well. Depletion of CD8+ cells resulted in delayed and only partial suppression, thereby suggesting that suppressor cells were CD8+. T cells cultured without MSCs ("precultured alone") did not suppress and even enhanced the mixed lymphocyte reaction. The suppressive effect of the suppressor T cells was observed in a mixed lymphocyte reaction induced by the same stimulator cells (Fig.2) as well as third party stimulators (Fig. 3).
Suppression of PHA-induced proliferation by pre-activated T cells cultured with MSCs: PBMC from donor 155 (autologous to suppressor cells) at 5 x 104 cells/well were stimulated with PHA-M (5 μg/ml) in the presence or absence of suppressor T cells. T cells from donor 155 were pre-activated by irradiated PBMC from donor 413 for 7 days as described above. These cells were cultured alone or with MSCs from donor 273 for 3 days (non-fractionated or CD8 depleted). Suppressor T cells were added at different number/well (from 5 x 104 cells/well to 1.56 x 103 cells/well). Cultures were incubated for 1, 2 or 3 days, then pulsed with [H3]TdR (5 Ci/mmol, 1 μCi/well) for an additional 18 hours.
The results are shown in Fig.4. Suppressor T cells suppressed PHA-induced proliferation of autologous PBMCs whereas T cells cultured alone accelerated the PHA response. Depletion of CD8 cells resulted in delayed and only partial suppression.

Claims

What Is Claimed Is:
1. A method for reducing an immune response against an alloantigen, comprising: contacting immune effector cells with suppressor cells in an amount effective to reduce the immune response.
2. The method of Claim 1 wherein the suppressor cells are T-cells.
3. The method of claim 1 wherein the effector cells are T cells.
4. A method of reducing an immune response to a donor transplant, comprising treating the recipient with suppressor T cells in an amount effective to reduce an immune response in the recipient to the transplant.
5. The method of claim 4 wherein the suppressor T cells are autologous to the recipient.
6. The method of claim 4, wherein the transplant is skin.
7. The method of claim 4, wherein the suppressor T cells are administered to the recipient prior to administration of the transplant.
8. The method of claim 4, wherein the suppressor T cells are administered concurrently with administration of the transplant.
9. The method of claim 4, wherein the suppressor T cells are administered as a part of the transplant.
10. The method of claim 4, wherein the suppressor T cells are administered after the transplant.
1 1. The method of claim 4 wherein the suppressor T cells are administered to the transplant recipient to treat rejection of the transplant by the recipient.
12. The method of claim 4, wherein suppressor T cells are human.
13. The method of claim 4, further comprising administering to the recipient immunosuppressive agents.
14. The method of claim 4 wherein the transplant is a solid organ.
15. The method of claim 14 wherein the solid organ is selected from heart, pancreas, kidney, lung, or liver.
16. A method of reducing an immune response caused by a donor transplant, comprising contacting the donor transplant with tissue obtained from the transplant recipient and then contacting the donor transplant with suppressor cells in an amount effective to reduce an immune response against the recipient by the donor transplant.
17. The method of Claim 16 wherein the suppressor cells are T-cells.
18. The method of claim 16 wherein the donor transplant is bone marrow.
19. The method of claim 16, further comprising administering to the recipient immunosuppressive agents.
20. A method of treating a transplant recipient for graft versus host disease, comprising treating the recipient of a donor transplant with suppressor T cells in an amount effective to reduce an immune response against the recipient by the transplant.
21. The method of claim 20, wherein the suppressor T cells are autologous to the recipient.
22. The method of claim 20, further comprising administering to the recipient immunosuppressive agents.
23. A composition for reducing an adverse immune response against a donor transplant, comprising human suppressor T cells in an amount effective to inhibit or reduce an adverse immune response against a donor transplant, and a pharmaceutical carrier.
24. A composition for reducing an adverse immune response against a graft recipient caused by a graft, comprising human suppressor T cells in an amount effective to reduce the adverse immune response against the graft recipient caused by the graft, and a pharmaceutical carrier.
25. A method of preparing suppressor cells, comprising: contacting activated immune effector cells with mesenchymal stem cells.
26. The method of Claim 25 wherein the immune effector cells are CD8+ cells.
27. The method of Claim 26 wherein the CD8+ cells are T-cells.
PCT/US2000/028011 1999-10-12 2000-10-10 Suppressor cells for prevention and treatment of immune responses in transplantation WO2001026470A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60026561T DE60026561T2 (en) 1999-10-12 2000-10-10 SUPPRESSOR CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATIONS
AU10778/01A AU775647B2 (en) 1999-10-12 2000-10-10 Suppressor cells for prevention and treatment of immune responses in transplantation
CA002382737A CA2382737A1 (en) 1999-10-12 2000-10-10 Suppressor cells for prevention and treatment of immune responses in transplantation
JP2001529270A JP2003511398A (en) 1999-10-12 2000-10-10 Suppressor cells used for prevention and treatment of immune response in transplantation
EP00972063A EP1220611B1 (en) 1999-10-12 2000-10-10 Suppressor cells for prevention and treatment of immune responses in transplantation
CY20061100708T CY1106437T1 (en) 1999-10-12 2006-06-02 SUPPRESSOR CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSES IN TRANSPLANTATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/415,627 US6685936B2 (en) 1999-10-12 1999-10-12 Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US09/415,627 1999-10-12

Publications (1)

Publication Number Publication Date
WO2001026470A1 true WO2001026470A1 (en) 2001-04-19

Family

ID=23646488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028011 WO2001026470A1 (en) 1999-10-12 2000-10-10 Suppressor cells for prevention and treatment of immune responses in transplantation

Country Status (12)

Country Link
US (2) US6685936B2 (en)
EP (1) EP1220611B1 (en)
JP (1) JP2003511398A (en)
AT (1) ATE319312T1 (en)
AU (1) AU775647B2 (en)
CA (1) CA2382737A1 (en)
CY (1) CY1106437T1 (en)
DE (1) DE60026561T2 (en)
DK (1) DK1220611T3 (en)
ES (1) ES2261250T3 (en)
PT (1) PT1220611E (en)
WO (1) WO2001026470A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875430B2 (en) * 1998-03-18 2005-04-05 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9408876B2 (en) * 2004-09-10 2016-08-09 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2001077299A2 (en) * 2000-04-11 2001-10-18 University Of Southern California A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
DK1349918T3 (en) * 2000-12-06 2014-11-10 Anthrogenesis Corp Method of collecting stem cells from placenta
EP2336299A1 (en) * 2001-02-14 2011-06-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
KR100973615B1 (en) * 2001-02-14 2010-08-02 안트로제네시스 코포레이션 Post-partum mammalian placenta, its use and placental stem cells therefrom
US7682803B2 (en) 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
JP2005531507A (en) * 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Method for local production and / or delivery of anticancer substances by stromal cell precursors
CN1717177A (en) * 2002-11-26 2006-01-04 人类起源公司 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
AU2004227342B2 (en) * 2003-04-01 2011-01-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
JP5089170B2 (en) * 2003-12-02 2012-12-05 セルジーン コーポレイション Methods and compositions for the treatment and management of abnormal hemoglobinosis and anemia
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
US20080241112A1 (en) * 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
PL1888123T3 (en) * 2005-06-08 2013-06-28 Janssen Biotech Inc A cellular therapy for ocular degeneration
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
ZA200804718B (en) 2005-12-29 2010-04-28 Anthrogenesis Corp Co-culture of placental stem cells and stem cells from a second source
ES2711278T3 (en) 2005-12-29 2019-04-30 Celularity Inc Populations of placental stem cells
WO2007087293A2 (en) 2006-01-23 2007-08-02 Athersys, Inc. Mapc therapeutics without adjunctive immunosuppressive treatment
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
CN101501185A (en) * 2006-06-09 2009-08-05 人类起源公司 Placental niche and use thereof to culture stem cells
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2420567A3 (en) 2006-10-23 2015-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
NZ578819A (en) * 2007-02-12 2012-02-24 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
EP2185693B1 (en) 2007-07-31 2019-07-03 Lifescan, Inc. Differentiation of human embryonic stem cells
KR101644659B1 (en) * 2007-09-26 2016-08-01 안트로제네시스 코포레이션 Angiogenic cells from human placental perfusate
EP3524253A1 (en) 2007-09-28 2019-08-14 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ES2595103T3 (en) 2007-10-17 2016-12-27 Txcell Tr1 cells, mesenchymal stem cells and uses of these
KR20160040739A (en) * 2007-11-07 2016-04-14 안트로제네시스 코포레이션 Use of umbilical cord blood in the treatment of premature birth complications
US9062290B2 (en) 2007-11-27 2015-06-23 Lifescan, Inc. Differentiation of human embryonic stem cells
MX2010009251A (en) 2008-02-21 2010-11-25 Centocor Ortho Biotech Inc Methods, surface modified plates and compositions for cell attachment, cultivation and detachment.
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology Methods and compositions for modulating immunological tolerance
CA2729734A1 (en) * 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
ES2697798T3 (en) 2008-06-30 2019-01-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
DK2330889T3 (en) * 2008-08-20 2017-01-30 Anthrogenesis Corp Improved cell composition and process for making the same
CA2734446C (en) * 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
CA2742268C (en) * 2008-10-31 2020-02-18 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
CN102333862B (en) * 2008-10-31 2018-04-27 詹森生物科技公司 Differentiation of the human embryo stem cell to pancreatic endocrine pedigree
KR20110086176A (en) 2008-11-19 2011-07-27 안트로제네시스 코포레이션 Amnion derived adherent cells
CA2744227C (en) * 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
AU2009316580B2 (en) 2008-11-20 2016-04-14 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
NZ602569A (en) * 2008-11-21 2014-03-28 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
GB2485113B (en) 2009-07-20 2016-12-28 Janssen Biotech Inc Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage
EP2456858B1 (en) * 2009-07-20 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR20170118969A (en) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
KR101861584B1 (en) * 2009-10-29 2018-05-28 얀센 바이오테크 인코포레이티드 Pluripotent stem cells
PL2516626T3 (en) * 2009-12-23 2017-10-31 Janssen Biotech Inc Differentiation of human embryonic stem cells
WO2011079017A2 (en) * 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
WO2011094181A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
SG10201501503VA (en) * 2010-03-01 2015-04-29 Janssen Biotech Inc Methods for purifying cells derived from pluripotent stem cells
HUE029144T2 (en) 2010-04-07 2017-02-28 Anthrogenesis Corp Angiogenesis using placental stem cells
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
DK2568991T6 (en) 2010-05-12 2019-03-18 Abt Holding Co MODULATION OF SPLENOCYTES IN CELL THERAPY
RU2663339C1 (en) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Differentiation of human embryo stem cells
CN103097520B (en) 2010-07-13 2017-12-05 人类起源公司 The method for producing NK
EP2611910B1 (en) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
BR112013004614A2 (en) 2010-08-31 2024-01-16 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS
EP3372672A1 (en) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN113559126A (en) 2011-06-01 2021-10-29 人类起源公司 Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
JP6441080B2 (en) 2011-12-22 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド Differentiation of human embryonic stem cells into single hormone insulin-positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP2859091B1 (en) 2012-06-08 2018-08-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
MX2015008619A (en) 2012-12-31 2016-01-12 Janssen Biotech Inc Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells.
RU2684215C2 (en) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Method for obtaining pancreatic endocrine cells (versions) and method for increasing output of beta cells
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
WO2014165581A1 (en) 2013-04-02 2014-10-09 New York University Gpr15-mediated homing and uses thereof
HUE052516T2 (en) 2013-04-12 2021-05-28 Houston Methodist Hospital Improving organs for transplantation
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
JP6783143B2 (en) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド Passive replenishment of medium
JP6588969B2 (en) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
CN106715676A (en) 2014-09-26 2017-05-24 泰尔茂比司特公司 Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11795433B2 (en) * 2017-05-23 2023-10-24 Creative Medical Technologies, Inc Generation of autologous immune modulatory cells for treatment of neurological conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788968A (en) * 1990-10-31 1998-08-04 Autoimmune, Inc. Methods and compositions for suppressing allograft rejection in mammals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
AU665042B2 (en) * 1991-11-05 1995-12-14 Board Of Trustees Of The Leland Stanford Junior University Suppressor and progenitor cells
KR960701988A (en) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR IN-FECTIOUS AGENTS
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
ATE316795T1 (en) * 1998-03-18 2006-02-15 Osiris Therapeutics Inc MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TREATMENT OF IMMUNE RESPONSE DURING TRANSPLANTATIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788968A (en) * 1990-10-31 1998-08-04 Autoimmune, Inc. Methods and compositions for suppressing allograft rejection in mammals

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GASSEL ET AL.: "The Role of T Suppressor Cells in the Maintenance of Spontaneously Accepted Orthotopic Rat Liver Allografts", TRANSPLANTATION, vol. 54, no. 6, December 1992 (1992-12-01), pages 1048 - 1053, XP002939119 *
KLYUSHNENKOVA ET AL.: "Human Mesenchymal Stem Cells Suppress Allogenic T Cell Responses In Vitro: Implications for Allogenic Transplantation", BLOOD, vol. 2, no. 10, 15 November 1998 (1998-11-15), pages 642A, XP002939120 *
PRITCHARD ET AL.: "Induction and Suppression of Delayed-Type Hypersensitivity to non-MHC Antigens During Lethal Graft-Versus-Host Reaction", J. IMMUNOLOGY, vol. 149, no. 1, 1 July 1992 (1992-07-01), pages 45 - 52, XP002939118 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875430B2 (en) * 1998-03-18 2005-04-05 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10716814B2 (en) 2004-03-22 2020-07-21 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10729727B2 (en) 2004-03-22 2020-08-04 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10828334B1 (en) 2004-03-22 2020-11-10 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10960025B2 (en) 2004-03-22 2021-03-30 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US11389484B2 (en) 2004-03-22 2022-07-19 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US9408876B2 (en) * 2004-09-10 2016-08-09 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation

Also Published As

Publication number Publication date
AU775647B2 (en) 2004-08-12
JP2003511398A (en) 2003-03-25
ATE319312T1 (en) 2006-03-15
DK1220611T3 (en) 2006-07-10
AU1077801A (en) 2001-04-23
DE60026561D1 (en) 2006-05-04
ES2261250T3 (en) 2006-11-16
PT1220611E (en) 2006-07-31
EP1220611A4 (en) 2004-12-22
CA2382737A1 (en) 2001-04-19
DE60026561T2 (en) 2007-03-15
US6281012B1 (en) 2001-08-28
US20020034504A1 (en) 2002-03-21
US6685936B2 (en) 2004-02-03
EP1220611A1 (en) 2002-07-10
CY1106437T1 (en) 2011-10-12
EP1220611B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
EP1220611B1 (en) Suppressor cells for prevention and treatment of immune responses in transplantation
English et al. Mesenchymal stromal cells: facilitators of successful transplantation?
Bordignon et al. Cell therapy: achievements and perspectives
Ge et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance
JP4740452B2 (en) Methods, compositions and methods of using mesenchymal stem cells for the prevention and treatment of immune responses in transplantation
CA2133316C (en) In vitro generation of human dendritic cells and uses thereof
JP5174656B2 (en) Materials and methods for modifying an immune response against exogenous and endogenous immunogens, including syngeneic or non-syngeneic cells, tissues or organs
Murphy et al. TNF‐α/IL‐1β—licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell‐mediated induction of Foxp3+ regulatory T cells in the lung
EP2269616A2 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
KR101578591B1 (en) Cell Therapy Composition for Preventing or Treating Immune Disease Comprising Mesenchymal Stem Cells and Immunoregulatory T-cells as active ingredient
JP2011037865A (en) Method to use fibroblast or supernatant from fibroblast for immune response inhibition in transplantation, and composition of the same
US8603815B2 (en) CD4+ CD25− T cells and Tr1-like regulatory T cells
Na et al. Prolongation of kidney allograft survival regulated by indoleamine 2, 3-dioxygenase in immature dendritic cells generated from recipient type bone marrow progenitors
Lloyd et al. Pancreas-graft immunogenicity and pretreatment with anti-class II monoclonal antibodies
Kapranov et al. Co-culturing of multipotent mesenchymal stromal cells with autological and allogenic lymphocytes
Thomson et al. Exposure to type-I collagen induces maturation of mouse liver dendritic cell progenitors
Schechter et al. Suppressor cells prevent host resistance to tumor growth
AU2005285222A1 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
EP1391210A2 (en) Regulatory medicament comprising CD4+CD25- T cells and Tr1-like regulatory cells
Onji et al. Dendritic Cells in Transplantation
WO2013040027A1 (en) Reprogramming immune environment in breast cancer via dendritic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2382737

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000972063

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 529270

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10778/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000972063

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 10778/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000972063

Country of ref document: EP